354-37-0

Basic information

• Product Name: Trifluoroacetamidine
• Synonyms: TRIFLUOROACETAMIDINE, TECH.;Trifluoroacetamidine;Trifluoroacetamideine;2,2,2-Trifluoroethanimidamide;EthaniMidaMide, 2,2,2-trifluoro-;2,2,2-trifluoroacetiMidaMide
• CAS NO: 354-37-0
• Molecular Formula: C₂H₃F₃N₂
• Molecular Weight: 112.05
• EINECS: -0
• Product Categories: Fluorochemicals
• Mol File: 354-37-0.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 35-37°C 11mm
• Flash Point: 35-37°C/11mm
• Appearance: /
• Density: 1.45
• Vapor Pressure: 2.16mmHg at 25°C
• Refractive Index: 1.3801
• Storage Temp.: Store below -20C
• PKA: 6.07±0.40(Predicted)
• Water Solubility: Fully miscible in water.
• Sensitive: Moisture Sensitive
• BRN: 605978
• CAS DataBase Reference: Trifluoroacetamidine(CAS DataBase Reference)
• NIST Chemistry Reference: Trifluoroacetamidine(354-37-0)
• EPA Substance Registry System: Trifluoroacetamidine(354-37-0)

Safety Data

• Hazard Codes: C,Xi
• Statements: 34
• Safety Statements: 26-36/37/39-45-20
• RIDADR: 3267
• HazardClass: 8
• PackingGroup: II
• Hazardous Substances Data: 354-37-0(Hazardous Substances Data)

Usage

Chemical Properties

Colorless liquid

Uses

Trifluoroacetamidine is used as probe for determination of membrane potential and extra/intracellular volume of erythrocytes by fluorine-19 NMR studies. It is a reagent used as protected ammonia equivalent.

InChI:InChI=1/C2H2F3NO/c3-2(4,5)1(6)7/h(H2,6,7)

Upstream product

• 354-38-1 2,2,2-trifluoroacetamide 
• 353-85-5 trifluoroacetonitrile 

Downstream Products

• 343-67-9 ethyl 2-(trifluoromethyl)-1,6-dihydro-6-oxopyrimidine-5-carboxylate 
• 524699-77-2 2,2,2-trifluoro-N'-(4-cyanophenyl)ethanehydrazonamide 
• 343-67-9 ethyl 4-hydroxy-2-trifluoromethylpyrimidine-5-carboxylate 
• 1207089-28-8 2,2,2-trifluoro-N'-(3-methyl-4-nitrobenzyl)ethanimide hydrazide 
• 902749-28-4 C₁₆H₁₀F₃N₅OS 
• 845618-08-8 5-chloro-2-(trifluoromethyl)pyrimidine 
• 647863-32-9 7,8-dibenzyl-2-(trifluoromethyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-ol 
• 647862-97-3 7-benzyl-2-(trifluoromethyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-ol 
• 915376-16-8 4-methyl-2-trifluoromethyl-pyrimidine-5-carboxylic acid methyl ester 
• 306960-67-8 ethyl 4-methyl-2-(trifluoromethyl)pyrimidine-5-carboxylate 
• 304693-64-9 ethyl 2-(trifluoromethyl)pyrimidine-5-carboxylate 
• 188781-15-9 ethyl 2,4-bis(trifluoromethyl)pyrimidine-5-carboxylate 
• 39560-95-7 2,2,2-trifluoroacetimidamide hydrochloride 
• 80862-25-5 2,4-bis(trifluoromethyl)-5-trifluoromethylthio-6-aminopyrimidine 

Relevant articles and documents

Preparation method of trifluoroacetamidine

The invention discloses a preparation method of trifluoroacetamidine, and belongs to the technical field of organic synthesis. Trifluoroacetamide is used as a raw material, gas-state trifluoroacetonitrile is collected through reflux and water diversion under the action of a catalyst, then trifluoroacetonitrile is introduced into DBU/liquid ammonia for a reaction, a polymerization inhibitor is added, distillation is performed, and trifluoroacetamidine is obtained. The method is coherent in reaction steps, simple and convenient to operate and high in yield; three wastes are reduced, the catalyst can be repeatedly utilized for more than 10 times in the dehydration process, the content of the obtained product is more than 99%, and the method has a potential industrial amplification prospect.

Drug synthesis intermediates for the preparation method of the (by machine translation)

The invention relates to the synthesis intermediate for the preparation method. In particular, the invention relates to a preparation under mild conditions the following formula 2 compound of preparation method, the states the equation below 2 of the cycloalkene compound 1 in the preparation of the compounds of use is necessary, the states the equation below 1 compound is used for the synthesis of inhibiting DPP - IV of the therapeutic agent for diabetes of the intermediate, the final high yield and purity of the formula 1 compound. Wherein R1, R2, R3, R4, R5 and P1 such as defined in the specification. (by machine translation)

2,4-Diazabicyclononane Skeletons from cis-Benzene Trioxide

By treating cis-benzene trioxide (1) with guanidine in buffered tert-butyl alcohol solution the 1:1-adducts DL-(1α,2β,4β,5α,6α,10α)-8-imino-3-oxa-7,9-diazatricyclo2,4>decane-5,10-diol (13a) and DL-(1α,2α,3β,5β,6α,7α)-9-imino-4-oxa-8,10-diazatricyclo3,5>decane-2,6-diol (12a) resulting from 1,3(1,2)-bridging in 1 are obtained in 88-91percent (9-12percent) yields.Trifluoroacetamidine (acetamidine) is also selectively 1,3-added to 1.From 13a via generally regiospecific hydrolysis (26a), thiolysis (30a, d), ammonolysis (34a), hydrazinolysis (34d), and HCl-/HBr-addition (39a, c) access to highly functionalised 2,4-diazabicyclononane derivatives is opened.During the "ring-chain tautomerism" observed for 26a and 34d (28a, 36d) the adamantoid orthocarbonic acid intermediates (27a, 35d) cannot be identified directly.The spectroscopic structure elucidations (not always unequivocal because i.a. of conformational flexibility of the skeletons) are confirmed by X-ray structural analysis for 29f, 36e, 38, and 43.